Sarah Hubbard Email and Phone Number

Part of leadership team within Regeneron's newly formed Genetic Medicines group. Leading high performing teams in the delivery of genetic therapies, using cutting edge technologies in the treatment of ALS, hemophilia, and other rare disease.

I had a dual role at Biogen as both a clinical operations program manager and an R&D project lead. As a R&D project lead, I was accountability for an early phase ASO asset for the treatment of a rare paediatric orphan disease. The R&D Project lead role meant I was the central point of accountability for the R&D project team, a high performing team of senior cross-functional representatives. This includes Commerical, Asset Management, Biostats, Clinical Pharmacology/ Toxicology as well as operations. My role was a strategic role, lead the team in preparation of governance and regulatory interactions, and asset progression. In my role as the operations program lead, I was accountability for the operational success of studies conducted to deliver the clinical development plan (CDP). I also sat at the R&D project team table as the operations representative. Through both of these roles, I had a keen vantage point on drug development- all the way from pre-clinical through to post-marketing. My role also involved direct involvement in interaction with external stakeholders, including advocacy groups and research partners. I was frequently asked to participate in alliance strategic meetings and to provide input into commercial activities such as press releases and business development, etc. I was been incredibly proud and grateful to lead a team that pioneered Biogen's first fully remote study, which has gained industry -wide recognition at the US Reuters Pharma awards in 2022, where we were joint runners up for the Inclusive Trials award. Key words: Genetic neuro degenerative disease, rare genetic disease, ASO development. Angelman Syndrome, Aicardi Goutieres Syndrome (AGS), Paediatrics, Pediatrics, KCNT1 epilepsy, governance, alliance, early phase

Associate Director, Late Phase Clinical Development & Operations, Medical Affairs Europe

Senior Manager (CPOM) overseeing high priority, pivotal International Phase II & Phase III programme.

Clinical Study Manager: European & International Phase III & IV interventional and non-interventional studies.

European Study Management

Local study manager - Sydney, Australia

Partly based in Phoeniz, AZ, USA